Clinical Importance of Drug-Drug Interactions
Clinical Importance of Drug-Drug Interactions
批准号:
8448598
负责人:
Sean Hennessy
金额:
$50.64万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-15 至 2017-03-31
关键词:
AddressAffectAgeAgreementAnticoagulationAntidiabetic DrugsAppearanceAttenuatedAwardBiologicalCharacteristicsClinicalCoagulation ProcessCollaborationsCytochrome P450DataData SetDatabasesDevelopmentDrug InteractionsDrug KineticsElderlyEsomeprazoleEventFenofibrateFibratesFrequenciesFutureGemfibrozilGlipizideGlyburideGoalsGrantHemorrhageHypoglycemiaImpact evaluationIn VitroIndianaInternational Normalized RatioIschemic StrokeKnowledgeLansoprazoleLipidsLovastatinMarketingMeasuresMedicare/MedicaidMetabolismMonitorOmeprazoleOralOutcomeP-GlycoproteinPatientsPharmaceutical PreparationsPioglitazonePolypharmacyPopulationPopulation DatabasePopulation StudyPravastatinProcessProton Pump InhibitorsPublic HealthRecommendationResearchRiskScienceSeriesSerumSimvastatinSourceStructureSulfonylurea CompoundsThromboembolismTimeUncertaintyUniversitiesUpdateVenousWarfarinatorvastatinbaseclinical effectclopidogrelcomputerizeddiabeticfluvastatingastrointestinalglucose monitorhuman CYP2C9 proteinin vivoindexinginnovationinterdisciplinary collaborationinterestmedical schoolspopulation basedprogramsrisk mitigationrosuvastatinsymposiumtool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Drug-drug interactions (DDIs) are a significant clinical and public health burden, especially for older adults. This burden will increase further as the population ages and the degree of polypharmacy increases. Knowledge about DDIs comes from many sources, with rigorous population-based studies of clinical outcomes providing the most clinically useful information. Because very few population DDI studies have been performed, there is profound disagreement among the DDI compendia about which drug pairs cause clinically important DDIs. Further, uncertainty about which potential DDIs are clinically important
has hampered efforts to mitigate the effects of DDIs, such as computerized decision support. Population studies of the clinical effects of DDIs are therefore badly needed, and should be integrated with research on the biological basis of DDIs. In this renewal application, we propose to extend our approach to population DDI studies in two important and innovative ways: 1) by actively and explicitly incorporating mechanistic considerations; and 2) by implementing a sequential approach of initially identifying and quantifying risk, then, where warranted based on this step, characterizing important DDIs further, with the goal of providing the basis for future efforts to mitigate risk. Based on an extensive and structured consultative process to identify research foci, we propose to conduct a series of population DDI studies using a large 5-state Medicaid/Medicare dataset. These studies will examine hypothesized interactions involving lipid lowering drugs, anti-clotting drugs, and oral anti-diabetic drugs, three drug classes with enormous relevance for older adults, and with high potential for causing clinically important DDIs. Thus, we will study potential DDIs of great clinical and public health importance, especially to older adults, and in the process develop data that will help elucidate the mechanisms of these potential DDIs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
-
批准号:10661090
-
项目类别:
-
资助金额:$76.24万
-
财政年份:2022
-
负责人:Sean Hennessy
-
依托单位:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
-
批准号:10501196
-
项目类别:
-
资助金额:$67.99万
-
财政年份:2022
-
负责人:Sean Hennessy
-
依托单位:
Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk
-
批准号:10662407
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2021
-
负责人:Sean Hennessy
-
依托单位:
Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk
-
批准号:10392130
-
项目类别:
-
资助金额:$36.25万
-
财政年份:2021
-
负责人:Sean Hennessy
-
依托单位:
Drug-Drug Interactions Involving Methadone and Buprenorphine
-
批准号:10436942
-
项目类别:
-
资助金额:$48.37万
-
财政年份:2019
-
负责人:Sean Hennessy
-
依托单位:
Enhancing the Utility of the Trend-in-Trend Research Design
-
批准号:10017817
-
项目类别:
-
资助金额:$54.92万
-
财政年份:2019
-
负责人:Sean Hennessy
-
依托单位:
Drug-Drug Interactions Involving Methadone and Buprenorphine
-
批准号:10205012
-
项目类别:
-
资助金额:$64.75万
-
财政年份:2019
-
负责人:Sean Hennessy
-
依托单位:
Drug-Drug Interactions Involving Methadone and Buprenorphine
-
批准号:10649570
-
项目类别:
-
资助金额:$45.94万
-
财政年份:2019
-
负责人:Sean Hennessy
-
依托单位:
Enhancing the Utility of the Trend-in-Trend Research Design
-
批准号:9813026
-
项目类别:
-
资助金额:$53.11万
-
财政年份:2019
-
负责人:Sean Hennessy
-
依托单位:
Enhancing the Utility of the Trend-in-Trend Research Design
-
批准号:10162467
-
项目类别:
-
资助金额:$56.18万
-
财政年份:2019
-
负责人:Sean Hennessy
-
依托单位:
Drug-Drug Interactions Involving Antidiabetic Agents
-
批准号:9282425
-
项目类别:
-
资助金额:$58.18万
-
财政年份:2014
-
负责人:Sean Hennessy
-
依托单位:
Drug-Drug Interactions Involving Antidiabetic Agents
-
批准号:8891420
-
项目类别:
-
资助金额:$58.92万
-
财政年份:2014
-
负责人:Sean Hennessy
-
依托单位:
Drug-Drug Interactions Involving Antidiabetic Agents
-
批准号:8748916
-
项目类别:
-
资助金额:$63.97万
-
财政年份:2014
-
负责人:Sean Hennessy
-
依托单位:
Ambulatory Care Access and Quality
-
批准号:8578341
-
项目类别:
-
资助金额:$47.66万
-
财政年份:2013
-
负责人:Sean Hennessy
-
依托单位:
Ambulatory Care Access and Quality
-
批准号:9313271
-
项目类别:
-
资助金额:$53.22万
-
财政年份:2013
-
负责人:Sean Hennessy
-
依托单位:
Ambulatory Care Access and Quality
-
批准号:8875037
-
项目类别:
-
资助金额:$52.11万
-
财政年份:2013
-
负责人:Sean Hennessy
-
依托单位:
Staging Activity Limitation
-
批准号:8910589
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2012
-
负责人:Sean Hennessy
-
依托单位:
Staging Activity Limitation
-
批准号:8699622
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2012
-
负责人:Sean Hennessy
-
依托单位:
Staging Activity Limitation
-
批准号:8518208
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2012
-
负责人:Sean Hennessy
-
依托单位:
Data Infrastructure for Post-Marketing Comparative Effectiveness Studies
-
批准号:7819258
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2009
-
负责人:Sean Hennessy
-
依托单位:
海外基金